Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.

European thyroid journal - 1 Jun 2024

Syed Abdul Rehman, Gorana Aakash, Nohr Erik, Yuan Xiaoli-Kat, Amin MASc Parthiv, Ghaznavi Sana, Lamb Debbie, McIntyre John, Eszlinger Markus, Paschke Ralf

Abstract excerpt

Context: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality. For rare NTRK and RET fusion-positive metastatic, RAI-resistant thyroid cancers, variable success of re-induction of RAI avidity during treatment with NTRK or RET inhibitors has been reported. Case presentation and results: We report two cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ETS Translocation Variant 6 Protein
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Proto-Oncogene Proteins c-ets

Share to Pyrazoles

Share to Receptor, trkA

Share to Receptor, trkC

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 38642578
DOI: 10.1530/ETJ-23-0227
PMCID: PMC11103761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.PMID 38642578Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.Semantic proximity Read ↗

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.Semantic proximity Read ↗

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity Read ↗

Efficacy of Radioiodine in Non-Distant Metastatic Papillary Thyroid Cancer with TERT-p Mutation at Initial DiagnosisSemantic proximity Read ↗

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.Semantic proximity Read ↗

IGF2 is a Potential Factor in RAI-refractory Non-medullary Thyroid CancerSemantic proximity Read ↗

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity Read ↗

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.Semantic proximity Read ↗

Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.Semantic proximity Read ↗

Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Semantic proximity Read ↗

Risk of second primary malignancy after radioiodine for thyroid carcinoma: a SEER-based studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.